The use of new antiretroviral therapy in combination with chemotherapy
- PMID: 9327224
- DOI: 10.1097/00001622-199709050-00010
The use of new antiretroviral therapy in combination with chemotherapy
Abstract
With rapid scientific advances in HIV pathogenesis and antiretroviral therapy, the oncologist is faced with new challenges in the treatment of patients with HIV infection and malignancy. HIV infection, by causing immune dysregulation and cytokine production, may alter the natural history of certain neoplasms. Treatment of cancer with chemotherapy can also affect the course of HIV disease. The use of combination antiretroviral agents, particularly the protease inhibitors, can maximally suppress replication of HIV. Improved clinical outcome is associated with more profound decreases in plasma HIV RNA, although development of resistant strains may hinder sustained antiretroviral activity. Antiretroviral therapy should be continued during chemotherapy with the goal of achieving plasma HIV-RNA levels below 500 copies/mL. Modifications in the regimen should be done when intolerable toxicity occurs or if viral load is increased. Although information regarding the use of newer antiretroviral agents with chemotherapy is limited, the use of several reverse transcriptase inhibitors has been well tolerated in patients with AIDS-related malignancies such as Kaposi's sarcoma and lymphoma.
Similar articles
-
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.AIDS. 1998 May 7;12(7):F45-9. doi: 10.1097/00002030-199807000-00002. AIDS. 1998. PMID: 9619797
-
Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma.Ann Oncol. 1998 Aug;9(8):923. doi: 10.1023/a:1008359628245. Ann Oncol. 1998. PMID: 9789620 Clinical Trial. No abstract available.
-
Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.J Natl Cancer Inst Monogr. 2001;(28):44-9. doi: 10.1093/oxfordjournals.jncimonographs.a024256. J Natl Cancer Inst Monogr. 2001. PMID: 11158206
-
Delavirdine: a review of its use in HIV infection.Drugs. 2000 Dec;60(6):1411-44. doi: 10.2165/00003495-200060060-00013. Drugs. 2000. PMID: 11152019 Review.
-
AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.Oncologist. 2005 Jun-Jul;10(6):412-26. doi: 10.1634/theoncologist.10-6-412. Oncologist. 2005. PMID: 15967835 Review.
Cited by
-
Lung cancer in HIV infected patients: facts, questions and challenges.Thorax. 2006 Nov;61(11):1000-8. doi: 10.1136/thx.2005.052373. Thorax. 2006. PMID: 17071836 Free PMC article. Review.
-
HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART.Adv Hematol. 2012;2012:507257. doi: 10.1155/2012/507257. Epub 2012 Jan 5. Adv Hematol. 2012. PMID: 22272202 Free PMC article.
-
HIV/AIDS-related lymphoma: perspective from a regional cancer center in India.Blood Res. 2019 Sep;54(3):181-188. doi: 10.5045/br.2019.54.3.181. Epub 2019 Sep 25. Blood Res. 2019. PMID: 31730692 Free PMC article.
-
A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma.Drug Saf. 1999 May;20(5):403-25. doi: 10.2165/00002018-199920050-00002. Drug Saf. 1999. PMID: 10348092 Review.
-
Eleven years of experience with AIDS-related lymphomas at the Institute of Oncology Ljubljana.Med Oncol. 2012 Jun;29(2):1217-22. doi: 10.1007/s12032-011-9951-7. Epub 2011 Apr 24. Med Oncol. 2012. PMID: 21516485
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical